JP5230549B2 - Cleaning method for medical equipment - Google Patents
Cleaning method for medical equipment Download PDFInfo
- Publication number
- JP5230549B2 JP5230549B2 JP2009159561A JP2009159561A JP5230549B2 JP 5230549 B2 JP5230549 B2 JP 5230549B2 JP 2009159561 A JP2009159561 A JP 2009159561A JP 2009159561 A JP2009159561 A JP 2009159561A JP 5230549 B2 JP5230549 B2 JP 5230549B2
- Authority
- JP
- Japan
- Prior art keywords
- component
- mass
- cleaning
- nonionic surfactant
- treatment liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Cleaning By Liquid Or Steam (AREA)
- Detergent Compositions (AREA)
Description
本発明は医療器具の洗浄方法に関する。 The present invention relates to a method for cleaning a medical instrument.
剪刀、鉗子、鑷子などの鋼製器具及び硬性ならびに軟性内視鏡などの医療器具は検査、治療、手術などに使用された後は、血液、体液などが付着する。これらの汚れには細菌、ウイルス、異常プリオンなどの病原性を有するタンパク質などが混在している可能性があり、確実に洗浄し消毒・滅菌した後、再使用する必要がある。その際、洗浄が不十分で汚れが残存していた場合、消毒や滅菌が期待されるほどの効果をあげることができず、完全な消毒や滅菌が達成できないことがあると言われている。また、洗浄工程において残存したタンパク質は、次工程で用いられるグルタールアルデヒドや過酢酸などの消毒剤あるいは高圧蒸気やエチレンオキサイドなどでの滅菌処理によりタンパク変性が起こり非常に強固で除去しにくい汚れとなる。そこで、消毒あるいは滅菌工程前にタンパク質汚れの洗浄を確実に行うため、中性酵素洗浄剤の使用が推奨されている(特許文献1)。また、近年では、中性酵素洗浄剤よりアルカリ系洗浄剤の方が洗浄性が高いことが判ってきたことから、洗浄機を用いた洗浄ではアルカリ系洗浄剤も使用されている。 Blood instruments, body fluids, and the like adhere to steel instruments such as scissors, forceps, and insulators and medical instruments such as rigid and flexible endoscopes after being used for examination, treatment, surgery, and the like. These stains may contain bacteria, viruses, pathogenic proteins such as abnormal prions, etc., and must be reused after being cleaned, disinfected and sterilized. At that time, if the cleaning is insufficient and dirt remains, it is said that the effect as much as disinfection and sterilization cannot be expected cannot be achieved and complete disinfection and sterilization may not be achieved. In addition, the protein remaining in the washing process is very strong and difficult to remove due to protein denaturation caused by sterilization with a disinfectant such as glutaraldehyde or peracetic acid used in the next process or high-pressure steam or ethylene oxide. Become. Therefore, the use of a neutral enzyme detergent is recommended in order to surely clean the protein soil before the disinfection or sterilization process (Patent Document 1). In recent years, it has been found that alkaline detergents have higher detergency than neutral enzyme detergents, and therefore, alkaline detergents are also used in washing using a washing machine.
医療現場でのこれらの洗浄剤を用いた洗浄性は、通常、目視で判定されており、目視で確認できる汚れが残存していれば再洗浄が行われている。しかしながら、最近の研究において、医療現場で使用された器具を市販の中性酵素洗浄剤やアルカリ洗浄剤を用いて洗浄した場合、ほとんどの器具は目視で残存汚れが無くなっているが、蛍光染色剤で染色後に蛍光顕微鏡を用いて詳細に観察すると固着したタンパク質汚れが残存していることが明らかになっている(非特許文献1)。 The detergency using these cleaning agents at the medical site is usually judged visually, and if dirt that can be visually confirmed remains, re-washing is performed. However, in recent research, when instruments used in the medical field are washed with a commercially available neutral enzyme cleaner or alkaline cleaner, most of the instruments are visually free of residual stains. When it is observed in detail using a fluorescence microscope after staining, it is revealed that the adhered protein stain remains (Non-Patent Document 1).
Journal of Hospital Infection (2008) 68, 52-58 Journal of Hospital Infection (2008) 68, 52-58
基材表面に固着した血液由来のタンパク質汚れは、除去が非常に困難であり、しかもその量は概ね1平方センチメール当たり数マイクログラム程度であると思われる。こうした基材表面に固着した血液由来のタンパク質汚れは、例えば、特許文献1の実施例で採用されている目視による判定方法や市販の測定キットによる判定方法では検出(残存の確認)が不可能である。また、特許文献1の実施例では、血液の凝固に関わる因子が除外された血液成分である血清を用いており、凝固して固着するような血液汚れは発生していない。従って、特許文献1は、基材表面に固着した血液由来のタンパク質汚れを除去できるような、より高度の洗浄については教示していない。なお、特許文献1に記載されているような洗浄剤組成物では、基材表面に固着した血液由来のタンパク質汚れを落とすことはできない。 The blood-derived protein soil adhering to the substrate surface is very difficult to remove, and the amount seems to be about several micrograms per square centimeter mail. Such blood-derived protein stains adhering to the substrate surface cannot be detected (remaining confirmation) by, for example, the visual determination method employed in the example of Patent Document 1 or the determination method using a commercially available measurement kit. is there. Moreover, in the Example of patent document 1, the serum which is the blood component from which the factor related to the coagulation of blood was excluded is used, and the blood dirt which coagulates and adheres does not generate | occur | produce. Therefore, Patent Document 1 does not teach a higher-level cleaning that can remove blood-derived protein soil adhered to the substrate surface. In addition, the detergent composition as described in Patent Document 1 cannot remove blood-derived protein stains adhered to the substrate surface.
医療器具に起因した院内感染を防止するために、このような微量かつ強固なタンパク質汚れを十分に除去することが重要であるが、従来、これを達成できる洗浄方法は見出されていない。 In order to prevent nosocomial infections caused by medical devices, it is important to sufficiently remove such a minute and strong protein stain, but no cleaning method that can achieve this has been found so far.
本発明の課題は、医療器具に固着したタンパク質汚れを効率的に除去できる洗浄方法を提供することである。 The subject of this invention is providing the washing | cleaning method which can remove efficiently the protein dirt which adhered to the medical device.
本発明は、(a)モノエタノールアミン〔以下、(a)成分という〕、(b)アルカリプロテアーゼ〔以下、(b)成分という〕、(c)非イオン界面活性剤〔以下、(c)成分という〕及び水を含有しpHが9以上である処理液を、タンパク質汚れが付着した医療器具に接触させる、医療器具の洗浄方法に関する。 The present invention comprises (a) monoethanolamine [hereinafter referred to as component (a)], (b) alkaline protease [hereinafter referred to as component (b)], (c) nonionic surfactant [hereinafter referred to as component (c). And a treatment liquid containing water and having a pH of 9 or more is brought into contact with a medical instrument on which protein soil adheres.
本発明によれば、医療器具に固着した、基材に固着した目視不可能なレベルのタンパク質汚れを効果的に除去することが可能な洗浄方法が提供される。 ADVANTAGE OF THE INVENTION According to this invention, the washing | cleaning method which can remove effectively the protein stain | pollution | contamination which cannot be visually observed adhered to the base material which adhered to the medical device can be provided.
(a)成分はモノエタノールアミンである。また、(a)成分以外のアルカリ剤〔以下、(a’)成分という〕を用いることもできる。(a’)成分としては、モノエタノールアミン以外のアルカノールアミン、アルカリ金属の水酸化物、炭酸塩、リン酸塩、珪酸塩から選ばれる一種以上を配合することが可能である。モノエタノノールアミン以外のアルカノールアミンとしては、ジエタノールアミン、トリエタノールアミン、N−メチルプロパノールアミン、2−アミノ−2−メチル−1−プロパノール等を挙げる事ができる。アルカリ金属の水酸化物、炭酸塩、リン酸塩、珪酸塩としては、水酸化カリウム、水酸化ナトリウム、炭酸カリウム、炭酸ナトリウム、リン酸カリウム、リン酸ナトリウム、1号珪酸カリウム、1号珪酸ナトリウム、2号珪酸カリウム、2号珪酸ナトリウム、オルト珪酸カリウム、オルト珪酸カリウムなどを挙げる事ができる。 The component (a) is monoethanolamine. Further, an alkali agent other than the component (a) [hereinafter referred to as the component (a ′)] can also be used. As the component (a ′), one or more selected from alkanolamines other than monoethanolamine, alkali metal hydroxides, carbonates, phosphates, and silicates can be blended. Examples of alkanolamines other than monoethanolanolamine include diethanolamine, triethanolamine, N-methylpropanolamine, and 2-amino-2-methyl-1-propanol. Alkali metal hydroxides, carbonates, phosphates and silicates include potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, potassium phosphate, sodium phosphate, No. 1 potassium silicate, No. 1 sodium silicate No. 2, potassium silicate, No. 2, sodium silicate, ortho orthosilicate, ortho orthosilicate, and the like.
(a)成分と(a’)成分の合計中の(a)成分の比率は、タンパク質汚れの除去効果の観点から、50質量%以上が好ましく、60質量%以上がより好ましく、70質量%以上がさらに好ましく、80質量%以上がさらにより好ましく、90質量%以上が特に好ましい。 The ratio of the component (a) in the total of the component (a) and the component (a ′) is preferably 50% by mass or more, more preferably 60% by mass or more, and 70% by mass or more from the viewpoint of the effect of removing protein stains. Is more preferable, 80% by mass or more is even more preferable, and 90% by mass or more is particularly preferable.
本発明に用いられる処理液中、(a)成分の含有量は、タンパク質汚れの除去効果及びコストや基材への影響性の観点から、0.004〜1質量%が好ましく、0.005〜0.5質量%がより好ましく、0.008〜0.2%質量%がさらに好ましく、0.01〜0.1%質量%がさらにより好ましい。 In the treatment liquid used in the present invention, the content of the component (a) is preferably 0.004 to 1% by mass, from the viewpoint of the effect of removing protein stains and cost and influence on the substrate, and is preferably 0.005 to 0.5 mass% is more preferable, 0.008-0.2% mass% is further more preferable, and 0.01-0.1% mass% is still more preferable.
また、(a’)成分を用いる場合は、本発明に用いられる処理液中、(a’)成分の含有量は、タンパク質汚れの除去効果を更に高める観点から、0.05質量%以下が好ましく、0.02質量%以下がより好ましく、0.01質量%以下がさらに好ましく、0.001質量%以下がさらにより好ましい。 Further, when the component (a ′) is used, the content of the component (a ′) in the treatment liquid used in the present invention is preferably 0.05% by mass or less from the viewpoint of further enhancing the effect of removing protein stains. 0.02% by mass or less is more preferable, 0.01% by mass or less is more preferable, and 0.001% by mass or less is even more preferable.
(b)成分であるアルカリプロテアーゼは、好ましくは中性からアルカリ側に至適pHが存在するものであれば如何なる酵素でもよく、またそれらの組合せも可能である。(b)成分はBacillus SPに由来するズブチリシンプロテアーゼが好ましく、中でも、Bacillus Halodurans、Bacillus clausiiに由来するズブチリシンプロテアーゼが好ましい。市販されているアルカリプロテアーゼとしては、例えば、花王(株)から入手できるKAP、ノボザイムズジャパン社から入手できるアルカラーゼ、サビナーゼ、エバラーゼ、エスペラーゼ、カンナーゼ、オボザイム、ジェネンコア・インターナショナル社から入手できるプラフェクト、プロペラーゼなどがある。 The alkaline protease as component (b) may be any enzyme as long as it has an optimum pH from neutral to alkaline, and combinations thereof are also possible. The component (b) is preferably a subtilisin protease derived from Bacillus SP, and among them, a subtilisin protease derived from Bacillus Halodurans or Bacillus clausii is preferred. Commercially available alkaline proteases include, for example, KAP available from Kao Corporation, Alcalase, Sabinase, Evalase, Esperase, Cannase, Obozyme, Genefector International, Plafect, Properase available from Novozymes Japan. and so on.
本発明に用いられる処理液中、(b)成分の含有量は、タンパク質汚れの除去効果及びコストの観点から、0.002〜1質量%が好ましく、0.005〜0.5質量%がより好ましく、0.008〜0.3質量%がさらに好ましく、0.01〜0.1%質量%がさらにより好ましい。 In the treatment liquid used in the present invention, the content of the component (b) is preferably 0.002 to 1% by mass, more preferably 0.005 to 0.5% by mass, from the viewpoint of the protein stain removal effect and cost. Preferably, 0.008 to 0.3% by mass is more preferable, and 0.01 to 0.1% by mass is even more preferable.
また、本発明の処理液中、(b)成分の含有量(タンパク質分解活性)は、固着タンパク質除去効果及びコストの観点から、処理液1kgあたり、0.01〜200PUが好ましく、0.025〜100PUがより好ましく、0.05〜20PUがさらに好ましい。 In addition, the content of the component (b) (proteolytic activity) in the treatment liquid of the present invention is preferably 0.01 to 200 PU per 1 kg of the treatment liquid from the viewpoint of the effect of removing the fixed protein and cost. 100PU is more preferable and 0.05-20PU is further more preferable.
なお、タンパク質分解活性(PU/g)は次の方法により測定される。
1w/v%の濃度でカゼイン(ハマーステイン:メルク社)を含む50mmol/Lホウ酸緩衝液(pH10.5)1mLを30℃で5分間保温した後、0.1gの酵素溶液と混合し、30℃で15分間反応を行う。反応停止液(0.11mol/Lトリクロロ酢酸−0.22mol/L酢酸ナトリウム−0.33mol/L酢酸)2mLを加え、室温で10分間放置する。次に酸変性タンパク質をろ過(No.2ろ紙;ワットマン社製)し、ろ液0.5mLにアルカリ性銅溶液[1w/v%酒石酸カリウム・ナトリウム水溶液:1w/v%硫酸銅水溶液:炭酸ナトリウムの0.1mol/L水酸化ナトリウム水溶液溶解物(炭酸ナトリウム濃度2w/v%)=1:1:100(V/V)]2.5mLを添加し30℃、10分間保温する。さらに、希釈フェノール試薬[フェノール試薬(関東化学社製)をイオン交換水で2倍に希釈したもの]0.25mLを加え、30℃で30分間保温後、このサンプルの660nmにおける吸光度を測定する。また、上記の酵素反応系に反応停止液を混合した後、酵素溶液を加えたものをブランクとして同様に吸光度を測定する。次にサンプルとブランクとの吸光度差により、遊離してきた酸可能性タンパク質分解物の量(チロシン換算された量)が得られ、これを反応時間(本条件の場合:15分)及び酵素溶液量(本条件の場合:0.1g)で除して、タンパク質分解活性値を求めることができる。なお、1PUは、上記の反応条件において1分間に1mmolのチロシンに相当する酸可溶性タンパク質分解物を遊離する酵素量とする。この方法で得られたタンパク質分解活性を基に上記の配合量が決定される。
The proteolytic activity (PU / g) is measured by the following method.
1 mL of 50 mmol / L borate buffer solution (pH 10.5) containing casein (Hammerstein: Merck) at a concentration of 1 w / v% was kept at 30 ° C. for 5 minutes, and then mixed with 0.1 g of enzyme solution. The reaction is performed at 30 ° C. for 15 minutes. Add 2 mL of the reaction stop solution (0.11 mol / L trichloroacetic acid-0.22 mol / L sodium acetate-0.33 mol / L acetic acid) and let stand at room temperature for 10 minutes. Next, the acid-denatured protein was filtered (No. 2 filter paper; manufactured by Whatman), and an alkaline copper solution [1 w / v% potassium tartrate / sodium tartrate aqueous solution: 1 w / v% copper sulfate aqueous solution: sodium carbonate was added to 0.5 mL of the filtrate. 0.1 mol / L aqueous sodium hydroxide solution (sodium carbonate concentration 2 w / v%) = 1: 1: 100 (V / V)] 2.5 mL is added, and the mixture is kept at 30 ° C. for 10 minutes. Further, 0.25 mL of a diluted phenol reagent [phenol reagent (manufactured by Kanto Chemical Co., Ltd.) diluted twice with ion-exchanged water] is added, and the mixture is incubated at 30 ° C. for 30 minutes, and then the absorbance at 660 nm of this sample is measured. Moreover, after mixing a reaction stop liquid with said enzyme reaction system, what added an enzyme solution is measured similarly as a blank. Next, the amount of acid proteolytic product that has been liberated (the amount converted to tyrosine) is obtained from the difference in absorbance between the sample and the blank, and this is the reaction time (in this case: 15 minutes) and the amount of enzyme solution. Dividing by (in the case of this condition: 0.1 g), the proteolytic activity value can be determined. Note that 1 PU is the amount of enzyme that liberates an acid-soluble proteolytic product corresponding to 1 mmol of tyrosine per minute under the above reaction conditions. The above blending amount is determined based on the proteolytic activity obtained by this method.
(c)成分は非イオン界面活性剤であり、タンパク質汚れの除去効果の観点から、下記(1)〜(3)からなる群から選ばれる1種以上の非イオン界面活性剤が好ましい。
(1)下記一般式(c1)で表される非イオン界面活性剤
RO−(EO)l−(PO)m−(EO)n−H (c1)
(Rは水素原子、又は炭素数6〜18の炭化水素基であり、Rが水素原子の場合、l、m、nは独立して1〜350の数であり、Rが炭素数8〜18の炭化水素基の場合、lは1〜10の数であり、m、nは独立して0〜15の数である。)
(2)炭素数6〜16の炭化水素基(好ましくはアルキル基又はアルケニル基)を有するアミンオキサイド
(3)炭素数6〜12の炭化水素基(好ましくはアルキル基又はアルケニル基)を有するグリセリルエーテル
Component (c) is a nonionic surfactant, and one or more nonionic surfactants selected from the group consisting of the following (1) to (3) are preferable from the viewpoint of the effect of removing protein stains.
(1) a nonionic surfactant represented by the following general formula (c1) RO- (EO) l - (PO) m - (EO) n -H (c1)
(R is a hydrogen atom or a hydrocarbon group having 6 to 18 carbon atoms, and when R is a hydrogen atom, l, m and n are each independently a number of 1 to 350, and R is a carbon number of 8 to 18) 1 is a number of 1 to 10, and m and n are independently a number of 0 to 15).
(2) Amine oxide having a hydrocarbon group having 6 to 16 carbon atoms (preferably an alkyl group or alkenyl group) (3) Glyceryl ether having a hydrocarbon group having 6 to 12 carbon atoms (preferably an alkyl group or alkenyl group)
(1)の非イオン界面活性剤について、一般式(c1)中のRが水素原子であるものは、重量平均分子量が1,000〜15,000のものが好ましく、一般式(c1)中のl、m、nは、この重量平均分子量となる数が好ましい。この非イオン界面活性剤は、例えば、プルロニック、プルロニックRという商品名でBASF社から入手可能である。 Regarding the nonionic surfactant of (1), those in which R in the general formula (c1) is a hydrogen atom preferably have a weight average molecular weight of 1,000 to 15,000, and in the general formula (c1) l, m, and n are preferably numbers corresponding to the weight average molecular weight. This nonionic surfactant is available from BASF, for example, under the trade names Pluronic and Pluronic R.
重量平均分子量とは、ゲル浸透クロマトグラフィ−(GPC:Gel permeation chromatography)により標準ポリエチレングリコールを用いて換算した重量平均分子量のことである。 The weight average molecular weight is a weight average molecular weight converted using standard polyethylene glycol by gel permeation chromatography (GPC).
(1)の非イオン界面活性剤について、一般式(c1)中のRが炭素数6〜18の炭化水素基であるものは、Rの炭素数は8〜16、更に8〜14が好ましい。また、Rはの炭化水素基は、好ましくはアルキル基又はアルケニル基であり、より好ましくは直鎖又は分岐鎖アルキル基、さらに好ましくは直鎖アルキル基である。また、lは2〜10の数が好ましく、m、nは0〜10の数が好ましい。この非イオン界面活性剤は、例えば、エマルゲンという商品名で花王(株)から、あるいはプルラファックという商品名でBASF社から入手可能である。 As for the nonionic surfactant (1), R in the general formula (c1) is a hydrocarbon group having 6 to 18 carbon atoms, and the carbon number of R is preferably 8 to 16, and more preferably 8 to 14. The hydrocarbon group for R is preferably an alkyl group or an alkenyl group, more preferably a linear or branched alkyl group, and still more preferably a linear alkyl group. L is preferably a number of 2 to 10, and m and n are preferably a number of 0 to 10. This nonionic surfactant can be obtained, for example, from Kao Corporation under the trade name Emulgen or from BASF under the trade name Pullurafac.
(2)の非イオン界面活性剤は、炭素数6〜16(好ましくは、炭素数6〜14、より好ましくは炭素数8〜12)のアルキル基又はアルケニル基(好ましくは直鎖又は分岐鎖アルキル基、より好ましくは直鎖アルキル基)を有するアミンオキサイドが好ましい。 The nonionic surfactant (2) is an alkyl group or alkenyl group (preferably linear or branched alkyl) having 6 to 16 carbon atoms (preferably 6 to 14 carbon atoms, more preferably 8 to 12 carbon atoms). Amine oxide having a group, more preferably a linear alkyl group) is preferred.
(3)の非イオン界面活性剤は、炭素数6〜12(好ましくは、炭素数6〜10、より好ましくは炭素数8〜10)のアルキル基又はアルケニル基(好ましくは直鎖又は分岐鎖アルキル基、より好ましくは分岐鎖アルキル基)を有するグリセリルエーテルが好ましい。 The nonionic surfactant (3) is an alkyl group or alkenyl group (preferably linear or branched alkyl) having 6 to 12 carbon atoms (preferably 6 to 10 carbon atoms, more preferably 8 to 10 carbon atoms). Group, more preferably a glyceryl ether having a branched alkyl group).
(1)〜(3)の非イオン界面活性剤の中では、タンパク質汚れの除去効果の観点から、(1)及び(2)からなる群から選ばれる1種以上の非イオン界面活性剤が好ましく、(1)から選ばれる1種以上の非イオン界面活性剤がより好ましい。なかでも、(1)の非イオン界面活性剤のうち、一般式(c1)中のRが炭素数6〜18の炭化水素基である非イオン界面活性剤が好ましい。 Among the nonionic surfactants (1) to (3), one or more nonionic surfactants selected from the group consisting of (1) and (2) are preferable from the viewpoint of the effect of removing protein stains. 1 or more types of nonionic surfactant chosen from (1) are more preferable. Among these, among the nonionic surfactants (1), nonionic surfactants in which R in the general formula (c1) is a hydrocarbon group having 6 to 18 carbon atoms are preferable.
本発明に用いられる処理液中、(c)成分の含有量は、タンパク質汚れの除去効果及びコストの観点から、0.002〜1質量%が好ましく、0.005〜0.5質量%がより好ましく、0.008〜0.3質量%がさらに好ましく、0.01〜0.1%質量%がさらにより好ましい。 In the treatment liquid used in the present invention, the content of the component (c) is preferably 0.002 to 1% by mass, more preferably 0.005 to 0.5% by mass, from the viewpoint of the protein stain removal effect and cost. Preferably, 0.008 to 0.3% by mass is more preferable, and 0.01 to 0.1% by mass is even more preferable.
本発明では、(a)成分、(b)成分、及び(c)成分が共存する所定pHの処理液を用いることで、血液等の汚れのうち、医療器具の硬質表面等に固着した汚れの上を覆っている目視可能な部分はもとより、基材表面に直接接触し固着したタンパク質汚れを十分に除去することができる。 In the present invention, by using a treatment solution having a predetermined pH in which the components (a), (b), and (c) coexist, among the stains such as blood, the stains adhered to the hard surface of the medical device. In addition to the visible portion covering the top, the protein stains that are in direct contact with and adhered to the substrate surface can be sufficiently removed.
本発明に用いられる処理液のpHは、9以上であり、タンパク質汚れの除去効果及び基材への影響性の観点から、9.5〜13が好ましく、10〜12がより好ましく、10.2〜11.5がさらに好ましい。 The pH of the treatment liquid used in the present invention is 9 or more, and preferably from 9.5 to 13, more preferably from 10 to 12, and more preferably from the viewpoint of the effect of removing protein stains and the influence on the substrate. More preferred is ˜11.5.
なお、pHは、本発明に用いられる処理液を25℃において測定して求めることができる。また、医療器具に接触させるときの処理液の温度におけるpHであってもよい。 In addition, pH can be calculated | required by measuring the process liquid used for this invention in 25 degreeC. Further, it may be the pH at the temperature of the treatment liquid when contacting the medical instrument.
本発明に用いられる処理液は、使用時に各成分を別個に添加し濃度調製を行う方法以外に、予め高濃度品を調製しておき、希釈時に設定濃度範囲に入るよう希釈する方法で調製することができる。高濃度品としては、(I)(a)成分、(b)成分及び(c)成分の3成分の全てを含有するもの、(II)(a)成分及び(b)成分を含有するもの、(III)(b)成分及び(c)成分を含有するものが挙げられ、酵素安定性の観点では(II)及び(III)が好ましい。また、(II)及び(III)では、最終的に配合される他の成分は、別に添加される。高濃度品は、例えば、水で10倍から200倍に希釈して使用することができる。 The treatment liquid used in the present invention is prepared by a method of preparing a high-concentration product in advance and diluting it to fall within the set concentration range at the time of dilution, in addition to the method of adjusting the concentration by adding each component separately at the time of use. be able to. As high-concentration products, those containing all three components (I) (a), (b) and (c), (II) those containing (a) and (b), (III) The component containing (b) component and (c) component is mentioned, (II) and (III) are preferable from a viewpoint of enzyme stability. Moreover, in (II) and (III), the other component finally mix | blended is added separately. A high-concentration product can be used, for example, diluted 10 to 200 times with water.
(a)成分、(b)成分及び(c)成分の3成分の全てを含有する高濃度品としては、(a)モノエタノールアミン0.4〜10質量%、(b)アルカリプロテアーゼ0.5〜10質量%、(c)非イオン界面活性剤1〜10質量%及び水を含有するものが挙げられ、該高濃度品は、更に、酵素活性の経時的劣化を防ぐ観点から、(d)エチレングリコール、プロピレングリコール、グリセリンから選ばれる1種以上を10〜70質量%含有することができる。 As a high concentration product containing all three components (a), (b) and (c), (a) monoethanolamine 0.4 to 10% by mass, (b) alkaline protease 0.5 -10% by mass, (c) 1-10% by mass of a nonionic surfactant and water are included, and the high-concentration product is further, from the viewpoint of preventing deterioration of enzyme activity over time, (d) 10-70 mass% of 1 or more types chosen from ethylene glycol, propylene glycol, and glycerol can be contained.
また、高濃度品は、酵素安定剤として水溶性カルシウム塩、ホウ酸またはその塩、ホウ砂等のホウ素化合物、ギ酸またはその塩を該高濃度品中に0.01〜5%含有することができる。 The high-concentration product may contain 0.01 to 5% of a water-soluble calcium salt, boric acid or a salt thereof, a boron compound such as borax, formic acid or a salt thereof as an enzyme stabilizer. it can.
本発明に用いられる処理液は、本発明の目的を損なわない範囲で、(c)成分以外の界面活性剤、アルカリ緩衝剤、ハイドロトロープ剤、pH調整剤、増粘剤、粘度調整剤、溶剤、香料、着色剤、酸化防止剤、防腐剤、漂白剤、漂白活性化剤などを配合することができる。これらの成分は、高濃度品に配合してもよい。 The treatment liquid used in the present invention is a surfactant other than the component (c), an alkali buffer, a hydrotrope, a pH adjuster, a thickener, a viscosity adjuster, and a solvent as long as the object of the present invention is not impaired. , Fragrances, colorants, antioxidants, preservatives, bleaches, bleach activators and the like can be blended. You may mix | blend these components in a high concentration goods.
本発明の対象となる医療器具としては、剪刀、鉗子、鑷子などの鋼製器具類、カテーテル、チューブ、バイトブロックなどの樹脂製器具、硬性もしくは軟性内視鏡等が挙げられる。処理液の接触は、これら医療器具の血液等に由来するタンパク質汚れが付着した部位と接触するように行われ、塗布、浸漬、噴霧などの方法により前記部位に適用することができる。処理液の温度は5〜50℃、更に10〜40℃が好ましい。また、接触時間は30秒〜30分、更に1分〜15分が好ましい。 Examples of medical instruments that are the subject of the present invention include steel instruments such as scissors, forceps, and insulators, resin instruments such as catheters, tubes, and bite blocks, and rigid or flexible endoscopes. The contact of the treatment liquid is performed so as to come into contact with a site where protein stains derived from blood or the like of these medical instruments are attached, and can be applied to the site by a method such as coating, dipping, or spraying. The temperature of the treatment liquid is preferably 5 to 50 ° C, more preferably 10 to 40 ° C. The contact time is preferably 30 seconds to 30 minutes, more preferably 1 minute to 15 minutes.
実施例1及び比較例1
表1の処理液を用いて、血液に由来するタンパク質汚れに対する洗浄効果を、目視判定法、タンパク質染色法、蛍光染色法の3つの方法で評価した。結果を表1に示す。
Example 1 and Comparative Example 1
Using the treatment liquid shown in Table 1, the cleaning effect on protein stains derived from blood was evaluated by three methods: a visual judgment method, a protein staining method, and a fluorescent staining method. The results are shown in Table 1.
〔I〕目視判定法及びタンパク質染色法
馬保存血1mLに対し、0.1%塩化カルシウムを50μL添加後、直ぐに攪拌した。これを20μL、30mm×80mmのテフロン(ポリテトラフルオロエチレン、登録商標)板上の直径15mmの円に均一に塗布し、室温で2時間30分乾燥してテストピースとした。
[I] Visual Judgment Method and Protein Staining Method 50 μL of 0.1% calcium chloride was added to 1 mL of horse-preserved blood and then immediately stirred. This was uniformly applied to a circle having a diameter of 15 mm on a Teflon (polytetrafluoroethylene, registered trademark) plate of 20 μL and 30 mm × 80 mm, and dried at room temperature for 2 hours and 30 minutes to obtain a test piece.
100mLのガラス製ビーカーに表1の処理液を100mL入れ、30℃とした。テストピースを20分間浸漬後、イオン交換水で静かに濯いだ。洗浄効果の効果は、目視で血液の残留があるかを判定した後、Coomassie Protein Assay Reagent(タンパク質定量キット添付の試薬、Thermo Scientific社製)に3分間浸漬後、イオン交換水で充分濯いだ後の染色状態で下記の判定基準に従い判定した。5回試験を行い、その平均値を表1に示した。なお、処理液は必要に応じ、乳酸でpHを調整した。
*目視判定基準
○:血液の残留は認められない。
△:わずかに血液の残留が認められる
×:多くの血液の残留が認められる。
In a 100 mL glass beaker, 100 mL of the treatment solution shown in Table 1 was placed at 30 ° C. The test piece was immersed for 20 minutes and then gently rinsed with ion exchange water. The effect of the cleaning effect was determined by visually checking for residual blood, then immersed in Coomassie Protein Assay Reagent (reagent supplied with a protein quantification kit, manufactured by Thermo Scientific) for 3 minutes, and then thoroughly rinsed with ion-exchanged water. It was determined according to the following criteria in the subsequent staining state. The test was conducted five times, and the average value is shown in Table 1. In addition, pH of the processing liquid was adjusted with lactic acid as needed.
* Visual criteria ○: No residual blood is observed.
Δ: Slight blood residue is observed. ×: Many blood residues are observed.
*染色後の判定基準
5:ほとんど染色されていない。
4:血液塗布面のほぼ半面以下が薄く染色される。
3:血液塗布面のほぼ半面以上が薄く染色される。
2:血液塗布面のほぼ半面以下が濃く染色される。
1:血液塗布面のほぼ半面以上が濃く染色される。
* Criteria after staining 5: Almost unstained.
4: Almost half or less of the blood application surface is lightly stained.
3: Almost half or more of the blood application surface is lightly stained.
2: Almost half or less of the blood application surface is deeply stained.
1: Almost half or more of the blood application surface is darkly stained.
〔II〕蛍光染色法
〔I〕と同様に洗浄したテストピースをSYPRO Ruby Protein Gel Stain(SIGMA社製)で10分間染色処理後、蒸留水でよく濯ぎ乾燥後、蛍光顕微鏡((株)キーエンス社製、Biozero)で20倍の対物レンズを用い、露光時間を変え470nmの励起光を照射し、510nm以上の反射光を検出することによりモニター上で観察し、下記の基準で判定した。短い露光時間で発色するほど、タンパク質量が多くなること意味する。
判定基準
5:露光時間3秒で、発色はほとんど認められない
4:露光時間3秒で、一部が発色する
3:露光時間0.4〜1秒で、ほぼ全面が発色している
2:露光時間0.05〜0.3秒で、ほぼ全面が発色している。
1:露光時間0.03秒で、ほぼ全面が発色している
[II] Fluorescent staining method The test piece washed in the same manner as in [I] is stained with SYPRO Ruby Protein Gel Stain (manufactured by SIGMA) for 10 minutes, rinsed thoroughly with distilled water, dried, and then fluorescence microscope (Keyence Corporation) Using a 20 × objective lens manufactured by Biozero, the exposure time was changed, irradiation with excitation light of 470 nm was performed, and reflected light of 510 nm or more was detected and observed on a monitor, and judged according to the following criteria. It means that the amount of protein increases as color develops in a shorter exposure time.
Criteria 5: Color development is hardly recognized at an exposure time of 3 seconds 4: Partial color development occurs at an exposure time of 3 seconds 3: Almost the entire surface is colored at an exposure time of 0.4 to 1 second 2: The entire surface is colored with an exposure time of 0.05 to 0.3 seconds.
1: The entire surface is colored with an exposure time of 0.03 seconds.
表中の成分は以下のものである。
・アルカリプロテアーゼ:KAP〔花王(株)製、2.2(PU/g)〕
・非イオン界面活性剤A:エマルゲン106〔ポリオキシエチレン(エチレンオキシド平均付加モル数6)ラウリルエーテル、花王(株)製〕
・非イオン界面活性剤B:エマルゲンLS106〔一般式(c1)においてl=3.0、m=1.5、n=3.0、Rが炭素数12のアルキル基、花王(株)製〕
・非イオン界面活性剤C:プルラファックLF901〔BASF社製〕
・非イオン界面活性剤D:ペネトールGE−EH(2−エチルヘキシルグリセリルエーテル、花王(株)製)
・非イオン界面活性剤E:アンヒトール20N(ラウリルジメチルアミンオキシド、花王(株)製)
The components in the table are as follows.
-Alkaline protease: KAP [manufactured by Kao Corporation, 2.2 (PU / g)]
Nonionic surfactant A: Emulgen 106 [polyoxyethylene (average number of moles of added ethylene oxide 6) lauryl ether, manufactured by Kao Corporation]
Nonionic surfactant B: Emulgen LS106 [in general formula (c1), l = 3.0, m = 1.5, n = 3.0, R is an alkyl group having 12 carbon atoms, manufactured by Kao Corporation]
・ Nonionic surfactant C: Plurafac LF901 (manufactured by BASF)
Nonionic surfactant D: Penetol GE-EH (2-ethylhexyl glyceryl ether, manufactured by Kao Corporation)
Nonionic surfactant E: Amphital 20N (Lauryldimethylamine oxide, manufactured by Kao Corporation)
表1に示されるように、(a)成分、(b)成分、及び(c)成分を含有し、pHが9以上である処理液を用いた実施例1−1〜1−7では、基材表面に固着したタンパク質汚れを効果的に除去できる。特に、本例で採用した蛍光染色法は、従来の判定法(アミドブラック染色やオルトトルイジン法等)では判別できない少量のタンパク質汚れの存在を確認できるものであるが、本発明の方法では、こうした精度の高い評価方法でもタンパク質汚れの存在はほとんど確認されず、優れた洗浄効果が得られていることがわかる。 As shown in Table 1, in Examples 1-1 to 1-7 using the treatment liquid containing the component (a), the component (b), and the component (c) and having a pH of 9 or more, Protein stains adhered to the material surface can be effectively removed. In particular, the fluorescent staining method employed in this example can confirm the presence of a small amount of protein stains that cannot be distinguished by conventional determination methods (such as amide black staining or orthotoluidine method). Even with a highly accurate evaluation method, the presence of protein contamination is hardly confirmed, indicating that an excellent cleaning effect is obtained.
一方、一般にタンパク質汚れは、pHを高めアルカリ性にするほど溶解性が高まり洗浄性が高くなると考えられているが、比較例1−1〜1−3のように(a)成分ではないアルカリ剤でpHをアルカリ領域とした系では、基材表面に固着したタンパク質汚れは完全に除去できていないことがわかる。 On the other hand, protein stains are generally considered to have higher solubility and higher detergency as the pH is increased and alkalinity. However, as in Comparative Examples 1-1 to 1-3, an alkaline agent that is not component (a) is used. It can be seen that in the system in which the pH is in the alkaline region, the protein soil adhered to the substrate surface cannot be completely removed.
また、(b)成分であるアルカリプロテアーゼを含まない処理液では、洗浄剤では、目視レベルの汚れは除去できるものの、比較例1−4のように、基材表面に固着したタンパク質汚れはほとんど除去できていないことがわかる。 Further, in the treatment liquid that does not contain the alkaline protease (b) component, the cleaning agent can remove stains at the visual level, but almost removes protein stains adhering to the substrate surface as in Comparative Example 1-4. You can see that it was not done.
また、(c)成分を含有しないと、比較例1−5のように、基材表面に固着した汚れは完全に除去できていないことがわかる。 Moreover, when (c) component is not contained, it turns out that the stain | pollution | contamination fixed to the base-material surface is not able to be removed completely like Comparative Example 1-5.
また、アルカノールアミンであってもジエタノールアミンやトリエタノールアミンを用いた場合は、比較例1−6、1−7のように、目視判定法では汚れが落ちているように見えても、蛍光染色法での評価が悪く基材表面に固着したタンパク質汚れが十分に除去できていないことがわかる。つまり、アルカノールアミンに属する化合物であっても、本発明の(a)成分のモノエタノールアミンでないと本発明の効果が得られないことがわかる。 Moreover, even if it is an alkanolamine, when diethanolamine or triethanolamine is used, as in Comparative Examples 1-6 and 1-7, even if it looks as if the dirt is removed by the visual judgment method, the fluorescent staining method It can be seen that the protein soil adhering to the substrate surface was not sufficiently removed because of poor evaluation at. That is, even if it is a compound which belongs to alkanolamine, the effect of this invention will not be acquired unless it is the monoethanolamine of (a) component of this invention.
また、(a)成分、(b)成分、及び(c)成分を含有する場合でも、pHを中性近傍にすると、比較例1−8のように、洗浄性は著しく低下することがわかる。なお、実施例1−7及び比較例1−8のpHは、クエン酸を添加して調整した。 Moreover, even when it contains (a) component, (b) component, and (c) component, when pH is made into neutral vicinity, it turns out that a washability falls remarkably like Comparative Example 1-8. In addition, pH of Example 1-7 and Comparative Example 1-8 was adjusted by adding citric acid.
本発明の洗浄方法の作用機構は明らかではないが、モノエタノールアミンと非イオン界面活性剤の作用により固着した汚れがアルカリプロテアーゼの作用を受けやすくさせるとともに、分解除去されたタンパク質汚れが非イオン界面活性剤により効果的に分散されたものと考えられる。
Although the mechanism of action of the cleaning method of the present invention is not clear, the soil fixed by the action of monoethanolamine and a nonionic surfactant is easily affected by the alkaline protease, and the protein soil that has been decomposed and removed is not a nonionic interface. It is thought that it was effectively dispersed by the activator.
Claims (5)
処理液中、(a)成分の含有量が0.004〜1質量%であり、(b)成分の含有量が0.002〜1質量%であり、(c)成分の含有量が0.002〜1質量%であり、
処理液中、(a’)モノエタノールアミン以外のアルカノールアミン、アルカリ金属の水酸化物、炭酸塩、リン酸塩、及び珪酸塩から選ばれる一種以上のアルカリ剤の含有量が0.05質量%以下である、
医療器具の洗浄方法。 (A) monoethanolamine (hereinafter referred to as component (a)), (b) alkaline protease (hereinafter referred to as component (b)), (c) nonionic surfactant (hereinafter referred to as component (c)) and water A method for cleaning a medical device, comprising the step of bringing a treatment liquid containing 9 and a pH of 9 or more into contact with a medical device to which protein soil has adhered ,
In the treatment liquid, the content of the component (a) is 0.004 to 1% by mass, the content of the component (b) is 0.002 to 1% by mass, and the content of the component (c) is 0.00. 002 to 1% by mass,
In the treatment liquid, the content of one or more alkali agents selected from (a ′) alkanolamines other than monoethanolamine, alkali metal hydroxides, carbonates, phosphates, and silicates is 0.05% by mass. Is
How to clean medical equipment.
(1)下記一般式(c1)で表される非イオン界面活性剤
RO−(EO)l−(PO)m−(EO)n−H (c1)
(式中、Rは水素原子、又は炭素数6〜18の炭化水素基であり、Rが水素原子の場合、l、m、nは独立して1〜350の数であり、Rが炭素数6〜18の炭化水素基の場合、lは1〜10の数であり、m、nは独立して0〜15の数である。)
(2)炭素数6〜16の炭化水素基を有するアミンオキサイド
(3)炭素数6〜12の炭化水素基を有するグリセリルエーテル The cleaning method according to claim 1 , wherein the component (c) is at least one nonionic surfactant selected from the group consisting of the following (1) to (3).
(1) a nonionic surfactant represented by the following general formula (c1) RO- (EO) l - (PO) m - (EO) n -H (c1)
(In the formula, R is a hydrogen atom or a hydrocarbon group having 6 to 18 carbon atoms, and when R is a hydrogen atom, l, m, and n are each independently a number of 1 to 350, and R is a carbon number. In the case of 6 to 18 hydrocarbon groups, l is a number from 1 to 10, and m and n are independently a number from 0 to 15.)
(2) Amine oxide having a hydrocarbon group having 6 to 16 carbon atoms (3) Glyceryl ether having a hydrocarbon group having 6 to 12 carbon atoms
RO−(EO)l−(PO)m−(EO)n−H (c1)
(式中、Rは炭素数6〜18の炭化水素基であり、lは1〜10の数であり、m、nは独立して0〜15の数である。) The method for cleaning a medical device according to claim 2 , wherein the component (c) is a nonionic surfactant represented by the following general formula (c1).
RO- (EO) l - (PO ) m - (EO) n -H (c1)
(In the formula, R is a hydrocarbon group having 6 to 18 carbon atoms, l is a number of 1 to 10, and m and n are independently a number of 0 to 15).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009159561A JP5230549B2 (en) | 2009-07-06 | 2009-07-06 | Cleaning method for medical equipment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009159561A JP5230549B2 (en) | 2009-07-06 | 2009-07-06 | Cleaning method for medical equipment |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011012219A JP2011012219A (en) | 2011-01-20 |
JP2011012219A5 JP2011012219A5 (en) | 2012-10-11 |
JP5230549B2 true JP5230549B2 (en) | 2013-07-10 |
Family
ID=43591426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009159561A Active JP5230549B2 (en) | 2009-07-06 | 2009-07-06 | Cleaning method for medical equipment |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5230549B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103261392B (en) * | 2010-12-28 | 2015-07-22 | 花王株式会社 | Method for cleaning medical appliance |
JP5407002B2 (en) * | 2012-05-28 | 2014-02-05 | 花王株式会社 | Cleaning composition for medical instrument washer |
CN103975048B (en) | 2012-05-28 | 2015-11-25 | 花王株式会社 | Endoscope cleaner cleanser compositions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001031999A (en) * | 1999-07-19 | 2001-02-06 | Clean Chemical Kk | Detergent composition |
JP4324363B2 (en) * | 2002-06-06 | 2009-09-02 | 花王株式会社 | Mutant alkaline protease |
JP2004000122A (en) * | 2002-03-22 | 2004-01-08 | Kao Corp | Alkaline protease |
JP2004305175A (en) * | 2003-04-10 | 2004-11-04 | Kao Corp | Alkali protease |
JP2008212084A (en) * | 2007-03-06 | 2008-09-18 | Kao Corp | Alkali protease |
JP2009034062A (en) * | 2007-08-03 | 2009-02-19 | Kao Corp | Alkaline protease |
-
2009
- 2009-07-06 JP JP2009159561A patent/JP5230549B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2011012219A (en) | 2011-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5584613B2 (en) | Cleaning method for medical equipment | |
CA2711226C (en) | Multiple enzyme cleaner for surgical instruments and endoscopes | |
WO2012090306A1 (en) | Method for cleaning medical appliance | |
JP5317466B2 (en) | Cleaning composition for medical equipment | |
JP5479894B2 (en) | Low foaming detergent | |
JP6770964B2 (en) | Liquid cleaning agent composition | |
US20100190676A1 (en) | Composition for enhanced removal of blood soils | |
US20150147802A1 (en) | Cleaning agent composition for medical-instrument cleaner | |
JP6732454B2 (en) | Cleaning disinfectant composition | |
CN108192771A (en) | A kind of two chamber multienzyme of surgical instrument coagulates pearl and preparation method thereof | |
JP5230549B2 (en) | Cleaning method for medical equipment | |
US10669513B2 (en) | Compositions and methods for handling potential prion contamination | |
JP2001031999A (en) | Detergent composition | |
JP2010235801A (en) | Cleaner composition | |
JP2004315691A (en) | Germicidal detergent composition | |
JP5587168B2 (en) | Cleaning composition for medical equipment | |
EP3423559B1 (en) | Non-enzymatic cleaner for reprocessing surgical instruments and flexible endoscopes | |
JP7511785B1 (en) | Liquid detergent composition and cleaning method using the same | |
JP6220652B2 (en) | Cleaning composition for medical equipment | |
US9045718B2 (en) | Residue cleaning composition and method | |
JPH05279700A (en) | Detergent composition | |
JP2022083462A (en) | Liquid detergent composition and cleaning method | |
JP2009073950A (en) | Powder detergent composition for linen supply | |
JPH05156294A (en) | Oxygen-containing liquid detergent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120608 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120823 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20121116 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20121210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121218 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130213 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130312 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130319 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160329 Year of fee payment: 3 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 5230549 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |